There is now considerable evidence that dynamic contrast agent-enhanced magnetic resonance imaging (MRI) data, when analyzed with appropriate pharmacokinetic models, are able to provide quantitative information regarding the vascular volume fraction (fvv), permeability-surface area product (PS), and contrast agent reflux rate (kR) in tumors. If shown to be accurate, such non-invasive measures will be highly useful in evaluating the efficacy of antiangiogenic therapies and in predicting how well chemotherapeutic agents will penetrate into tumors through diffusive and convective processes. Limited, and often contradictory, studies have been performed to date to correlate MRI-derived in vivo measures of fvv, PS, and kR with existing """"""""gold standards"""""""" such as immunohistochemistry-based measures of microvessel density and vascular permeability. Furthermore, rigorous comparisons of MRI-derived measures obtained using FDA-approved low molecular weight contrast media with those obtained using theoretically advantageous higher molecular weight media currently in clinical trials are limited. Such studies are needed to establish the limitations of using each class of contrast media in assessing fvv, PS, and kR. These issues must be resolved prior to the application of such promising non-invasive measures to clinical monitoring of the efficacy of antiangiogenic therapy. The overall goals of this project are to 1) demonstrate that accurate in vivo quantitative measures of fvv, PS, and kR can be obtained via single and/or dual tracer pharmacokinetic modeling of dynamic contrast agent-enhanced MRI data, and 2) correlate such measures, in both animal models and human studies, with other surrogate markers of angiogenesis, including expression of specific angiogenic factors, proteases, rates of endothelial cell apoptosis, and endothelial cell-specific markers.
The specific aims i n this project are: 1) correlation of single and dual tracer pharmacokinetic measures of fvv, PS, and kR obtained using high, medium, and low molecular weight contrast agents with immunohistochemical and radionuclide determinations of microvessel density and vascular permeability; 2) acquisition of longitudinal pharmacokinetic measures of fvv, PS, and kR in subcutaneously implanted tumors treated with antiangiogenic therapies, and correlation of these measures with other surrogate markers of angiogenesis and vascular permeability; and 3) acquisition of longitudinal pharmacokinetic measures in patients enrolled in clinical trials of antiangiogenic drugs, and correlation of these measures with other invasive surrogate markers of angiogenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA090810-02
Application #
6563961
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-01-01
Project End
2002-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
2
Fiscal Year
2002
Total Cost
$296,752
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Wang, Ruoning; Jung, Sung Yun; Wu, Chuan Fen et al. (2010) Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation. Proc Natl Acad Sci U S A 107:19885-90
Kopetz, Scott; Hoff, Paulo M; Morris, Jeffrey S et al. (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453-9
Connelly, Sarah F; Isley, Beth A; Baker, Cheryl H et al. (2010) Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells. Mol Carcinog 49:1007-21
Trepel, Martin; Stoneham, Charlotte A; Eleftherohorinou, Hariklia et al. (2009) A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer. Mol Cancer Ther 8:2383-91
Ng, Chaan S; Kodama, Yoshihisa; Mullani, Nizar A et al. (2009) Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. J Comput Assist Tomogr 33:460-5
Wang, Wei; Shao, Ruping; Wu, Qingping et al. (2009) Targeting gelatinases with a near-infrared fluorescent cyclic His-Try-Gly-Phe peptide. Mol Imaging Biol 11:424-33
Kim, M P; Park, S I; Kopetz, S et al. (2009) Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 335:249-59
Kopetz, Scott; Lesslie, Donald P; Dallas, Nikolas A et al. (2009) Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69:3842-9
Nie, Jing; Chang, Benny; Traktuev, Dmitry O et al. (2008) IFATS collection: Combinatorial peptides identify alpha5beta1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells. Stem Cells 26:2735-45
Urbanczyk-Pearson, Lauren M; Femia, Frank J; Smith, Jeffrey et al. (2008) Mechanistic investigation of beta-galactosidase-activated MR contrast agents. Inorg Chem 47:56-68

Showing the most recent 10 out of 84 publications